---
title: "Glaucoma Surgery"
order: 2
category: "Ophthalmology"
---

# Glaucoma Surgery

## Overview

Glaucoma surgery aims to lower intraocular pressure (IOP) to prevent progressive optic nerve damage and vision loss. When medical therapy (topical medications) and laser treatments fail to adequately control IOP, surgical intervention becomes necessary. Traditional filtration surgery (trabeculectomy) creates a new drainage pathway for aqueous humor, while tube shunt procedures provide controlled drainage through an implanted device. Recent advances in minimally invasive glaucoma surgery (MIGS) offer less invasive options with faster recovery and fewer complications. The choice of surgical approach depends on glaucoma type, severity, prior surgeries, and patient factors.

## Aqueous Humor Dynamics and IOP

### Aqueous Production

**Site**: Ciliary body (nonpigmented epithelium)
**Rate**: ~2-3 μL/min
**Mechanism**: Active secretion (carbonic anhydrase-dependent), ultrafiltration
**Circadian variation**: Higher during day, lower at night

### Aqueous Flow

**Pathway**:
1. Produced in posterior chamber (behind iris)
2. Flows through pupil to anterior chamber
3. Exits via trabecular meshwork or uveoscleral pathway

### Aqueous Outflow

**Conventional Pathway** (80-90%):
- **Trabecular meshwork** → Schlemm's canal → Collector channels → Episcleral veins
- **Site of resistance**: Juxtacanalicular meshwork (primary site of pathology in POAG)

**Uveoscleral Pathway** (10-20%):
- Through ciliary muscle bundles → Suprachoroidal space → Scleral emissaries
- Pressure-independent

### Intraocular Pressure

**Normal**: 10-21 mmHg (mean 15-16 mmHg)
**Determinants**: Aqueous production, outflow resistance
**Equation**: IOP = (Aqueous production / Outflow facility) + Episcleral venous pressure

## Glaucoma Types and Surgical Indications

### Primary Open-Angle Glaucoma (POAG)

**Most common** type requiring surgery
**Pathophysiology**: Increased resistance in trabecular meshwork
**Surgical indications**: Failed maximum medical therapy, intolerance to medications, non-compliance, progressive optic nerve damage despite treatment

### Angle-Closure Glaucoma

**Acute**: Laser peripheral iridotomy (LPI) first-line
**Chronic**: May require filtration surgery if IOP uncontrolled post-LPI

### Secondary Glaucomas

**Neovascular Glaucoma**:
- New vessel formation (diabetes, central retinal vein occlusion)
- Poor prognosis, often requires tube shunt (trabeculectomy high failure rate)

**Uveitic Glaucoma**: Inflammation-related, higher surgical failure rate

**Traumatic Glaucoma**: Angle damage from trauma

**Pseudoexfoliation**: Severe IOP elevation, aggressive course

### Congenital/Pediatric Glaucoma

**Primary congenital glaucoma**: Goniotomy, trabeculotomy first-line
**Refractory cases**: Trabeculectomy, tube shunt

### General Surgical Indications

- Progressive visual field loss despite maximum medical therapy
- IOP above target (individualized based on severity, life expectancy)
- Inability to use/afford medications
- Non-compliance with medical therapy

## Laser Procedures

### Laser Trabeculoplasty

**Selective Laser Trabeculoplasty (SLT)**:
- **Mechanism**: Q-switched Nd:YAG laser (532nm) targets pigmented trabecular meshwork cells, improves outflow
- **Indications**: POAG, ocular hypertension (first-line or adjunct to medications)
- **Technique**: 50-100 spots over 180-360° of trabecular meshwork
- **Efficacy**: Lowers IOP 20-30% (6-9 mmHg reduction)
- **Duration**: Effect wanes over years (median 3-5 years), repeatable
- **Complications**: Transient IOP spike, inflammation (rare)

**Argon Laser Trabeculoplasty (ALT)**: Older technique, more tissue damage, less commonly used now

### Laser Peripheral Iridotomy (LPI)

**Indications**: Angle-closure glaucoma (narrow angles, pupillary block)
**Technique**: Nd:YAG laser creates hole in peripheral iris (allows aqueous to flow from posterior to anterior chamber)
**Location**: Superior iris (under eyelid, cosmetically hidden)
**Complications**: Transient IOP spike, bleeding, inflammation

### Cyclophotocoagulation

**Indications**: Refractory glaucoma, poor surgical candidates
**Mechanism**: Laser ablates ciliary body (reduces aqueous production)
**Types**:
- **Transscleral cyclophotocoagulation**: Diode laser through sclera
- **Endoscopic cyclophotocoagulation (ECP)**: Intraocular, more controlled
**Complications**: Pain, inflammation, hypotony, phthisis (chronic)

## Trabeculectomy

### Principle

Create a **guarded fistula** from anterior chamber to subconjunctival space, forming a **filtering bleb** (subconjunctival aqueous reservoir that drains into episcleral vessels/lymphatics)

### Indications

- POAG uncontrolled on maximum medical therapy
- Secondary open-angle glaucomas
- **Preferred** in patients without prior conjunctival surgery (scarring reduces success)

### Surgical Technique

**Anesthesia**: Local (retrobulbar or peribulbar block) or general

**Steps**:

1. **Fornix-based or Limbus-based Conjunctival Flap**:
   - Limbus-based (more traditional): Conjunctival incision at limbus, dissect posteriorly
   - Fornix-based: Incision at fornix, better postoperative comfort

2. **Partial-thickness Scleral Flap**:
   - Create rectangular or triangular scleral flap (4x4mm, 3x3mm)
   - Thickness: 1/3 to 1/2 scleral thickness
   - Hinged anteriorly at limbus

3. **Antimetabolite Application**:
   - **Mitomycin-C (MMC)** or **5-Fluorouracil (5-FU)**
   - **Purpose**: Inhibit fibroblast proliferation, prevent bleb scarring
   - **Application**: Sponge soaked with MMC (0.2-0.4 mg/mL) applied to episclera/Tenon's for 1-5 minutes
   - **Rinse thoroughly** (prevent excessive tissue damage)

4. **Sclerostomy/Trabeculectomy**:
   - Remove block of tissue (trabecular meshwork, Schlemm's canal, deep sclera) at scleral flap base
   - Creates fistula from anterior chamber to subconjunctival space
   - Size: ~1-2mm

5. **Peripheral Iridectomy**:
   - Remove small portion of peripheral iris
   - **Purpose**: Prevent iris from plugging sclerostomy

6. **Scleral Flap Closure**:
   - Suture flap with releasable or adjustable sutures (10-0 nylon)
   - **Tension**: Tight enough to prevent hypotony but allow controlled aqueous flow
   - **Adjustable**: Can cut/laser sutures postoperatively to titrate IOP

7. **Conjunctival Closure**:
   - Watertight closure (10-0 nylon or vicryl)

**Postoperative IOP Titration**:
- **Laser suture lysis**: Cut scleral flap sutures to increase flow (lower IOP) if target not met
- **Bleb needling**: Break down scar tissue (if bleb failing)

### Postoperative Management

**Medications**:
- **Topical steroids**: Prednisolone acetate 1%, frequent dosing (q1-2h initially), prolonged taper (months)
  - Critical to prevent scarring
- **Cycloplegics**: Atropine (reduce inflammation, prevent pupillary block)
- **Antibiotics**: Topical (first week)

**Follow-Up**:
- **Frequent**: POD 1, week 1, then q1-2 weeks for months
- **Assess**: IOP, bleb morphology, anterior chamber depth, complications

**Bleb Morphology**:
- **Ideal**: Diffuse, elevated, avascular (light filtering)
- **Failing**: Flat, vascularized, encapsulated

### Complications

**Early**:
- **Hypotony** (IOP <5 mmHg):
  - **Causes**: Overfiltration, wound leak, cyclodialysis
  - **Consequences**: Choroidal effusion, macular edema, vision loss
  - **Management**: Reduce steroids (if overfiltration), patch/bandage contact lens (if leak), surgical revision
- **Shallow/Flat Anterior Chamber**:
  - **Causes**: Overfiltration, pupillary block, choroidal effusion, aqueous hyposecretion
  - **Management**: Depends on cause (atropine, reform AC, surgical intervention)
- **Hyphema**: Blood in anterior chamber (usually self-limited)
- **Choroidal Effusion/Hemorrhage**: Hypotony-related, suprachoroidal fluid/blood

**Late**:
- **Bleb Failure/Scarring** (30-50% at 5 years):
  - **Cause**: Fibroblast proliferation, excessive scarring
  - **Management**: Bleb needling with antimetabolite injection, revision surgery
- **Hypotony Maculopathy**: Chronic hypotony causes macular folds, vision loss
- **Cataract** (20-30%): Accelerated cataract formation post-trabeculectomy
- **Bleb-related Infection/Endophthalmitis** (1-2% lifetime risk):
  - **Thin avascular blebs** at risk
  - **Presentation**: Bleb purulence, hypopyon, vision loss
  - **Management**: Culture, intravitreal antibiotics, often vitrectomy
  - **Prevention**: Avoid inferior blebs (exposure to lids, increased infection risk)
- **Blebitis**: Bleb infection without intraocular extension (milder than endophthalmitis)

### Outcomes

**Success** (IOP <21 mmHg without medications):
- **1 year**: 70-90%
- **5 years**: 50-70%
- **With medications**: Higher success

**Factors Affecting Success**:
- **Favorable**: First surgery, no prior conjunctival surgery, adequate antimetabolite use
- **Unfavorable**: Prior failed surgery, young age, neovascular/uveitic glaucoma, African descent (more aggressive scarring)

## Tube Shunt Surgery (Glaucoma Drainage Devices)

### Principle

Implantable device diverts aqueous from anterior chamber to equatorial subconjunctival/subTenon's space via silicone tube

### Types

**Non-Valved (Flow-Restricted)**:
- **Baerveldt**, **Molteno**
- **Mechanism**: Fixed plate size limits flow (larger plate = lower IOP)
- **Requires temporary occlusion** of tube (internal ligature, external stent) to prevent early hypotony (until capsule forms around plate)

**Valved**:
- **Ahmed**
- **Mechanism**: Valve opens when IOP exceeds threshold (~8-10 mmHg)
- **No occlusion needed** (valve prevents early hypotony)
- **Trade-off**: Higher long-term IOP than non-valved (hypertensive phase common)

**Plate Sizes**: 250-350mm² (Ahmed, Baerveldt)

### Indications

- **Failed trabeculectomy**
- **Neovascular glaucoma** (high trabeculectomy failure rate)
- **Uveitic glaucoma**
- **Pediatric glaucoma** (refractory)
- **Conjunctival scarring** (prior surgery, chemical injury)
- **Active proliferative retinopathy** (avoid trabeculectomy - risk of bleb hemorrhage)

**Tube vs. Trabeculectomy** (TVT Study):
- Similar IOP lowering and success rates
- Tube: Fewer early complications, more late complications (corneal edema)
- Trabeculectomy: Lower IOP achieved but higher failure rate

### Surgical Technique

**Steps**:

1. **Conjunctival Incision**: Expose superotemporal or superonasal quadrant

2. **Plate Fixation**:
   - Suture plate to sclera 8-10mm posterior to limbus (equator)
   - Between extraocular muscle insertions (superior and lateral rectus)

3. **Tube Preparation**:
   - Cut tube to appropriate length (3mm into anterior chamber)
   - **Bevel** tube tip (reduce iris/corneal touch)
   - **Non-valved**: Ligate tube or insert internal stent (remove later)

4. **Anterior Chamber Entry**:
   - Create scleral track (23-gauge needle) 1-2mm posterior to limbus into anterior chamber
   - Insert tube through track into anterior chamber

5. **Tube Coverage**:
   - Cover extraocular tube with **patch graft** (donor sclera, cornea, pericardium)
   - **Purpose**: Prevent erosion through conjunctiva

6. **Conjunctival Closure**: Watertight

**Postoperative**:
- **Non-valved**: Remove ligature/stent at 4-6 weeks (allow capsule to form around plate)
- **Ahmed**: No ligature needed

### Complications

**Early**:
- **Hypotony** (Ahmed less common due to valve)
- **Hyphema**: Tube trauma to iris
- **Shallow anterior chamber**
- **Choroidal effusion**

**Intermediate**:
- **Hypertensive Phase** (Ahmed, 30-50%):
  - Transient IOP elevation (months 1-3 post-op)
  - **Cause**: Fibrosis around plate (before capsule matures)
  - **Management**: Resume glaucoma medications, usually resolves

**Late**:
- **Tube Erosion** (5-10%):
  - Tube erodes through conjunctiva
  - **Risk**: Infection, endophthalmitis
  - **Management**: Patch graft revision
- **Tube Obstruction**: Blood, fibrin, iris tissue
- **Corneal Decompensation** (5-10%):
  - Tube proximity to corneal endothelium
  - May require corneal transplant
- **Diplopia**: Plate bulk restricts motility (rare)
- **Encapsulation/Fibrosis**: Thick capsule around plate, elevated IOP
  - **Management**: Needling, capsulotomy, revision

### Outcomes

**Success** (IOP <21 mmHg, >5 mmHg):
- **1 year**: 80-90%
- **5 years**: 60-70%

**IOP Lowering**: ~30-40% reduction from baseline

## Minimally Invasive Glaucoma Surgery (MIGS)

### Overview

**Characteristics**:
- Ab interno approach (through cornea, minimize conjunctival manipulation)
- Minimal tissue trauma
- Faster recovery, fewer complications than traditional surgery
- **Limitation**: Modest IOP lowering (typically 20-30% reduction)

**Indications**: Mild-moderate glaucoma, often combined with cataract surgery

### Trabecular Bypass Stents

**iStent/iStent Inject**:
- **Mechanism**: Titanium microstent bypasses trabecular meshwork, drains to Schlemm's canal
- **Technique**: Ab interno, inserted through trabecular meshwork into Schlemm's canal (gonioscopy visualization)
- **IOP Lowering**: 20-25% (6-8 mmHg), reduces medication burden
- **Combination**: Often combined with cataract surgery
- **Complications**: Minimal (stent obstruction, malposition)

**Hydrus Microstent**:
- Scaffold device placed in Schlemm's canal (dilates canal, enhances outflow)
- Similar efficacy to iStent

### Trabecular Ablation

**Trabectome**:
- **Mechanism**: Electrocautery ablates trabecular meshwork (360° or less)
- **IOP Lowering**: 25-30%
- **Complications**: Hyphema (common, self-limited), IOP spike

**Kahook Dual Blade (KDB)**:
- **Mechanism**: Goniotomy (excision of trabecular meshwork strip)
- **IOP Lowering**: Similar to Trabectome

**Gonioscopy-Assisted Transluminal Trabeculotomy (GATT)**:
- Catheter threaded 360° through Schlemm's canal, then withdrawn to tear trabecular meshwork
- **IOP Lowering**: 30-40% (more than other MIGS)

### Suprachoroidal Shunts

**CyPass** (withdrawn from market 2018 due to endothelial cell loss)

**iStent Supra**:
- Shunt diverts aqueous to suprachoroidal space (uveoscleral pathway)
- Still investigational

### Subconjunctival MIGS

**XEN Gel Stent**:
- **Mechanism**: Soft gelatin stent (6mm long) creates fistula from anterior chamber to subconjunctival space (like trabeculectomy)
- **Insertion**: Ab interno (through cornea), tunnels through sclera to conjunctiva
- **Bleb formation**: Creates filtering bleb (requires antimetabolite - MMC)
- **IOP Lowering**: 30-40% (more than other MIGS, closer to trabeculectomy)
- **Complications**: Bleb-related (similar to trabeculectomy but lower rate), hypotony, need for needling

### MIGS Outcomes

**IOP Reduction**: 15-30% (less than trabeculectomy/tube shunt)
**Medication Reduction**: Significant
**Safety Profile**: Excellent (fewer complications than traditional surgery)
**Ideal Patient**: Mild-moderate glaucoma, combined with cataract surgery

## Special Considerations

### Pediatric Glaucoma

**Primary**: Goniotomy, trabeculotomy first-line (angle surgery)
**Refractory**: Trabeculectomy (higher failure rate in children), tube shunt

### Neovascular Glaucoma

**Management**:
- **Anti-VEGF** (bevacizumab, ranibizumab): Regress new vessels before surgery
- **Panretinal photocoagulation**: Treat underlying ischemia
- **Surgery**: Tube shunt preferred (trabeculectomy high failure rate)

### Uveitic Glaucoma

**Challenges**: Inflammation increases surgical failure
**Management**: Control inflammation pre/post-operatively, consider tube shunt

### Prior Vitrectomy

**Effect**: Faster aqueous flow through vitrectomized eye (risk of hypotony)
**Adjust**: Tighter scleral flap sutures, smaller sclerostomy

## Outcomes and Prognosis

### IOP Lowering Comparison

- **Trabeculectomy**: 40-50% reduction (IOP 10-14 mmHg typical)
- **Tube Shunt**: 30-40% reduction (IOP 12-16 mmHg typical)
- **MIGS**: 20-30% reduction (IOP 15-18 mmHg typical)
- **Laser (SLT)**: 20-30% reduction (IOP 15-18 mmHg typical)

### Visual Outcomes

**Preserved vision**: Goal is to prevent further vision loss (not improve vision)
**Cataract**: Accelerated formation (20-30% after trabeculectomy)
**Central visual acuity**: Usually preserved unless complications (hypotony maculopathy, endophthalmitis)

### Revision Surgery

**Indications**: Bleb failure, inadequate IOP control
**Options**: Bleb needling, repeat trabeculectomy, tube shunt (if failed trabeculectomy), cyclophotocoagulation

## Key Points

- Glaucoma surgery indicated when medical therapy fails to prevent progression; goal is IOP reduction to prevent further optic nerve damage
- Aqueous humor flows from ciliary body → posterior chamber → pupil → anterior chamber → trabecular meshwork → Schlemm's canal → episcleral veins
- Trabeculectomy creates guarded fistula from anterior chamber to subconjunctival bleb; requires antimetabolite (MMC) to prevent scarring
- Tube shunt devices divert aqueous to equatorial plate; valved (Ahmed) vs non-valved (Baerveldt) differ in early hypotony risk and long-term IOP
- Trabeculectomy complications: early hypotony (overfiltration), bleb failure (30-50% at 5 years), late endophthalmitis (1-2% lifetime risk)
- Tube shunt complications: hypertensive phase (Ahmed, 30-50%), corneal decompensation (5-10%), tube erosion (5-10%)
- MIGS procedures (iStent, Trabectome, XEN) offer safer profile but more modest IOP lowering (20-30% vs 40-50% for trabeculectomy)
- Selective laser trabeculoplasty (SLT) first-line alternative to surgery; lowers IOP 20-30%, effect lasts 3-5 years, repeatable
- Neovascular glaucoma requires anti-VEGF + panretinal photocoagulation pre-surgery; tube shunt preferred (trabeculectomy high failure)
- TVT Study showed similar efficacy for tube vs trabeculectomy; tube had fewer early complications but more late corneal decompensation
- Bleb-related endophthalmitis most feared late trabeculectomy complication; thin avascular blebs highest risk; lifetime risk 1-2%
- Postoperative trabeculectomy management critical: laser suture lysis to titrate IOP, prolonged steroid taper (months), frequent follow-up

## References

1. Gedde SJ, et al. Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study. Ophthalmology. 2012;119(4):703-10
2. American Academy of Ophthalmology. Primary Open-Angle Glaucoma, Preferred Practice Pattern (2020)
3. Jampel HD, et al. Perioperative complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS). Am J Ophthalmol. 2005;140(1):16-22
4. Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23(2):96-104
5. Gedde SJ, et al. Primary Tube Versus Trabeculectomy Study (PTVT). Ophthalmology. 2018;125(12):1815-1819
